Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Bank of America Securities

In a report released today, Geoff Meacham from Bank of America Securities maintained a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report). The company’s shares opened today at $9.05.

Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna. According to TipRanks, Meacham has an average return of 3.0% and a 49.46% success rate on recommended stocks.

Neumora Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $29.00, implying a 220.44% upside from current levels. In a report released on May 7, RBC Capital also maintained a Buy rating on the stock with a $29.00 price target.

NMRA market cap is currently $1.47B and has a P/E ratio of -5.66.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neumora Therapeutics, Inc. (NMRA) Company Description:

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.